Statins and neuroprotection

Expert Opinion on Investigational Drugs

Volumn 10, Issue 10, 2001, Pages 1847-1853

  Sheehy, N ^a   Vaughan, C J ^a   Delanty, N ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Dementia; Endothelium; HMG CoA reductase inhibitors; Neuroprotection; Nitric oxide; Statins; Stroke

Indexed keywords

ATORVASTATIN; FARNESYL DIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; BRAIN; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMENTIA; DRUG METABOLISM; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; META ANALYSIS; MOUSE; NEUROPROTECTION; NONHUMAN; PARENCHYMA; PRIMARY PREVENTION; RAT; REVIEW; RISK; SECONDARY PREVENTION; STROKE;

ANIMALS; CEREBROVASCULAR ACCIDENT; DEMENTIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEUROPROTECTIVE AGENTS;

EID: 0034779891     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.10.1847     Document Type: Review

References (59)

1. Neuroprotective properties of statins in cerebral ischemia and stroke
2. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
3. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration
4. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program
5. Risk factors for cerebral haemorrhage and cerebral infarction in a Japanese rural community
6. Blood pressure, cholesterol, and stroke in eastern Asia
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
9. Stroke, statins, and cholesterol. A meta-analysis of randomised, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors
10. Reductase inhibitor monotherapy and stroke prevention
11. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)
12. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolaemia: Report from the Program on the Surgical Control of the Hyperlipidemias (POSCH)
13. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomised, controlled trials
14. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
16. Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes: The MIRACL study: A randomised controlled trial
17. [Does statin therapy reduce incidence of stroke? A meta-analysis]
18. Vascular effects of statins in stroke
19. Statins and the risk of dementia
20. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors
21. Nitric oxide synthase in models of focal ischaemia
22. Differential regulation by cytokines of human astrocyte nitric oxide production
23. Inducible nitric oxide synthase expression in human cerebral infarcts
24. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine
25. Delayed reduction of ischaemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene
26. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice
27. Stroke protection by 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
28. Regulation of endothelial NO production by Rho GTPase
29. Inducible nitric-oxide synthase and nitric oxide production in human fetal astrocytes and microglia. A kinetic analysis
30. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages
31. Cytokines and cell adhesion molecules in cerebral ischaemia: Experimental bases and therapeutic perspectives
32. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolaemic rats
33. Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet-activating factor
34. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolaemia
35. Effect of mevalonate availability on the association of G-protein alpha-subunits with the plasma membrane in GH4C1 cells
36. Postischemic administration of an anti-Mac-1 antibody reduces ischaemic cell damage after transient middle cerebral artery occlusion in rats
37. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells
38. Interleukin-1 beta mRNA expression in ischaemic rat cortex
39. Altered neuronal and microglial responses to excitotoxic and ischaemic brain injury in mice lacking TNF receptors
40. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
41. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat
42. Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events
43. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
44. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilisation
45. Role of oxidants in ischaemic brain damage
46. Oxidative injury in the nervous system
47. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the 'response to injury' hypothesis
48. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolaemic effect of the drug and its binding to the LDL
49. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine
50. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
51. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia
52. Lovastatin decreases coenzyme Q levels in humans
53. 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects
54. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease
55. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study
56. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study
57. Association between Alzheimer's disease and the NOS3 gene
58. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER)
59. Does Pretreatment With Statins Improve Clinical Outcome After Stroke?: A Pilot Case-Referent Study